Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.69 |
| ▸ | CDK8 | P49336 | 6/20 | 0.50 |
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | ROS1 | P08922 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28081590 | 0.89 | AXL (0.62) | RIPK1CDK8AXLIMPDH2IMPDH1 | |
| SCHEMBL30569001 | 0.82 | RIPK1 (0.49) | RIPK1CDK8AXLIMPDH2IMPDH1 | |
| SCHEMBL31065011 | 0.82 | RIPK1 (1.00) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL2013329 | 0.81 | RIPK1 (0.51) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL293195 | 0.81 | RIPK1 (0.51) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL17761629 | 0.79 | RIPK1 (0.49) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL1329244 | 0.77 | CDK8 (0.58) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL1484205 | 0.76 | RIPK1 (0.64) | RIPK1CDK8AXLIMPDH2IMPDH1 | |
| SCHEMBL297592 | 0.76 | RIPK1 (0.47) | RIPK1CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL29543783 | 0.76 | RIPK1 (0.47) | RIPK1CDK8AXLPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| CN-109311874-A | The bicyclic heterocyclic compounds being substituted | 百时美施贵宝公司 | 2019-02-05 | — | — | CN | claimed |
| EP-3313840-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210034-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | claimed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | claimed |
| EP-2496086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | claimed |
| EP-2250170-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Merck Patent GmbH (DE) | 2010-11-17 | — | — | EP | claimed |
| WO-2009112139-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK PATENT GMBH, (DE) | 2009-09-17 | — | — | WO | claimed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | claimed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2005062795-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RIPK1 62/4885CDK8 646/4885AXL 356/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | RIPK1 2007/4885CDK8 1873/4885AXL 3473/4885 |
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | RIPK1 143/4885CDK8 362/4885AXL 3946/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | RIPK1 152/4885CDK8 360/4885AXL 3999/4885 |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KIT, LTK, HRH3 | RIPK1 1259/4885CDK8 257/4885AXL 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.